bioAffinity Technologies, Inc. (BIAFW) stock
BIAFWNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 4/3056% below fair value
$0.24+0.00 (0.00%)
Close on Oct 30, 2026Market cap $23.58MP/E –Yield –
bioAffinity Technologies operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
bioAffinity Technologies's operating income for the twelve months ending Jun 30, 2026 was -$12.38M. For fiscal 2025 it was -$10.57M. The highest annual figure on record is -$2.21M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$10.57M | – |
| FY2024 | Dec 31, 2024 | -$8.95M | – |
| FY2023 | Dec 31, 2023 | -$7.97M | – |
| FY2022 | Dec 31, 2022 | -$4.01M | – |
| FY2021 | Dec 31, 2021 | -$2.21M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.33M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.62M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.14M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.29M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.52M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.63M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.95M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.97M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.09M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.95M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.34M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.29M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.78M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.56M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.62M | – |
| Q3 FY2022 | Sep 30, 2022 | -$976.16K | – |
| Q2 FY2022 | Jun 30, 2022 | -$684.12K | – |
| Q1 FY2022 | Mar 31, 2022 | -$727.04K | – |
| Q4 FY2021 | Dec 31, 2021 | -$659.75K | – |
| Q3 FY2021 | Sep 30, 2021 | -$526.29K | – |